
    
      This is a randomized, double blind, placebo controlled, parallel group, multicenter study to
      demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg)
      once daily compared to placebo in subjects with SAR. This study was previously posted by
      Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and
      in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
    
  